about possible modifications before coming to the meeting.

Agenda: The committee will discuss, make recommendations, and vote on a premarket approval application, sponsored by TherOx, Inc., for the TherOx Aqueous Oxygen System (AO System). The system is intended for use in acute myocardial infarction (AMI) patients, who have undergone successful revascularization less than or equal to 6 hours from symptom onset. These patients were randomized to AO Therapy or not. The endpoint is reduction in the final size of the infarct. The system draws blood from the patient, hyperoxygenates it with the AO cartridge component of the system, and reinfuses the blood via the infusion catheter directly to the infarction site of the heart. This therapy is intended to be performed for 90 minutes post percutaneous coronary intervention/ stenting.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at http://www.fda.gov/ohrms/ dockets/ac/acmenu.htm, click on the year 2009 and scroll down to the appropriate advisory committee link.

*Procedure*: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before March 4, 2009. Oral presentations from the public will be scheduled approximately 30 minutes at the beginning of committee deliberations and approximately 30 minutes near the end of the deliberations. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before February 25, 2009. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons

regarding their request to speak by February 26, 2009.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact AnnMarie Williams, Conference Management Staff, at 240–276–8932, at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at *http://www.fda.gov/oc/advisory/ default.htm* for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: February 10, 2009.

#### Randall W. Lutter,

Deputy Commissioner for Policy. [FR Doc. E9–3488 Filed 2–18–09; 8:45 am] BILLING CODE 4160–01–S

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

## National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel, Sexually Transmitted Infections Cooperative Research Centers.

*Date:* March 3–5, 2009.

*Time:* 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

*Place:* The Crowne Plaza Hotel, 8777 Georgia Avenue, Silver Spring, MD 20910. *Contact Person:* Michelle M. Timmerman, PhD, Scientific Review Officer, Scientific Review Program, NIH/NIAID/DHHS, Room 3147, 6700B Rockledge Drive, MSC–7616, Bethesda, MD 20892–7616, 301–451–4573, *timmermanm@niaid.nih.gov.* 

**NAME OF COMMITTEE:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel, Review of Unsolicited P01 Application.

*Date:* March 10, 2009.

*Time:* 11 a.m. to 2 p.m.

Agenda: To review and evaluate grant applications.

*Place:* National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).

Contact Person: Eleazar Cohen, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, NIAID/NIH/DHHS, Room 3129, 6700B Rockledge Drive, Bethesda, MD 20892, (301) 435–3564, ec17w@nih.gov.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel, Review of Unsolicited P01 Application.

*Date:* March 12, 2009.

*Time:* 11 a.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).

*Contact Person:* Eleazar Cohen, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, NIAID/NIH/DHHS, Room 3129, 6700B Rockledge Drive, Bethesda, MD 20892, (301) 435–3564, ec17w@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: February 11, 2009.

#### Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–3437 Filed 2–18–09; 8:45 am] BILLING CODE 4140-01-P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Substance Abuse and Mental Health Services Administration

## Center for Substance Abuse Treatment; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of the meeting of the Center for Substance Abuse Treatment (CSAT) National Advisory Council on March 19, 2009.

The meeting is open to the public and will include discussion of the Center's policy issues, and current administrative, legislative, and program developments. Attendance by the public will be limited to space available. Public comments are welcome. Please communicate with the CSAT Council's Designated Federal Official, Ms. Cynthia Graham (see contact information below), to make arrangements to attend, comment or to request special accommodations for persons with disabilities.

Substantive program information, a summary of the meeting, and a roster of Council members may be obtained as soon as possible after the meeting, either by accessing the SAMHSA Committee Web site, http://www.nac.samhsa.gov/ CSAT/csatnac.aspx, or by contacting Ms. Graham. The transcript for the meeting will also be available on the SAMHSA Committee Web site within three weeks after the meeting.

*Committee Name:* Substance Abuse and Mental Health Services Administration, CSAT National Advisory Council.

*Date/Time/Type:* March 19, 2009, From 8:30 a.m.–5 p.m.: Open.

*Place:* 1 Choke Cherry Road, Sugarloaf and Seneca Conference Rooms, Rockville, Maryland 20857.

*Contact:* Cynthia Graham, M.S., Designated Federal Official, SAMHSA/CSAT National Advisory Council, 1 Choke Cherry Road, Room 5–1036, Rockville, MD 20857, Telephone: (240) 276–1692, FAX: (240) 276– 1690, e-mail:

cynthia.graham@samhsa.hhs.gov.

#### Toian Vaughn,

Committee Management Officer, Substance Abuse and Mental Health, Services Administration.

[FR Doc. E9–3469 Filed 2–18–09; 8:45 am] BILLING CODE 4162–20–P

#### DEPARTMENT OF HOMELAND SECURITY

## **Coast Guard**

[USCG-2009-0065]

#### National Offshore Safety Advisory Committee

**AGENCY:** Coast Guard, DHS. **ACTION:** Notice of open teleconference meeting.

**SUMMARY:** On February 13, 2009, the Coast Guard published a **Federal Register** notice announcing a teleconference meeting of the National Offshore Safety Advisory Committee (NOSAC). NOSAC will discuss data on foreign vessels arriving on the U.S. Outer Continental Shelf from abroad as well as other items that it may consider. This notice supplements that original teleconference meeting notice.

**ADDRESSES:** The Committee will meet, via telephone conference, on February

26, 2009. Members of the public interested in participating in the teleconference may contact Commander P.W. Clark at 202–372–1410 for call in information or they may participate in person by coming to Room 1303, U.S. Coast Guard Headquarters Building, 2100 Second Street, SW., Washington, DC 20593. As there are a limited number of teleconference lines, public participation will be on a first come basis. Members of the public may submit written comments to Commander P.W. Clark, Designated Federal Officer of NOSAC, Commandant (CG-5222), 2100 Second Street, SW., Washington, DC 20593–0001; or by fax to 202-372-1926. Comments should reach Commander P.W. Clark on or before February 25, 2009. The teleconference meeting notice, and this supplemental notice is available on our online docket, USCG-2009-0065, at http://www.regulations.gov.

### FOR FURTHER INFORMATION CONTACT:

Commander P.W. Clark, Designated Federal Officer of NOSAC, or Mr. Jim Magill, Assistant Designated Federal Officer, telephone 202–372–1414, fax 202–372–1926.

SUPPLEMENTARY INFORMATION: Notice of this teleconference meeting is given under the Federal Advisory Committee Act, 5 U.S.C. App. 2. The teleconference meeting agenda was published as part of the original notice on February 13, 2009, which can be found in the Federal **Register** at 72 FR 7243. The Federal Advisory Committee Act requires Federal Register publication 15 days prior to a meeting held in accordance with the Act. The original NOSAC teleconference meeting announcement was published in the Federal Register 13 days prior to the meeting due to delays in the renewal of the NOSAC Charter. Further, due to scheduling conflicts, we were unable to delay this teleconference to a date past February 26, 2009.

The Coast Guard has made all known interested parties aware of the teleconference meeting with sufficient time for planning purposes.

## M.L. Blair,

Acting Director of Commercial Regulations and Standards.

[FR Doc. E9-3558 Filed 2-18-09; 8:45 am] BILLING CODE 4910-15-P

## DEPARTMENT OF HOMELAND SECURITY

## U.S. Citizenship and Immigration Services

[CIS No. 2468–09; DHS Docket No. USCIS– 2009–0001; RIN No. 1615–ZA81]

### Announcement of a Stakeholder Meeting on the E-Verify Program in Arizona

**AGENCY:** U.S. Citizenship and Immigration Services, DHS. **ACTION:** Notice of meeting.

**SUMMARY:** The E-Verify Program is a free employment eligibility confirmation system operated jointly by U.S. Citizenship and Immigration Services (USCIS) and the Social Security Administration. It is designed to provide the best means available for determining employment eligibility of new hires and the validity of their Social Security numbers. The E-Verify Program allows participating employers to electronically confirm the employment eligibility of newly hired employees to help maintain a stable, legal workforce. The purpose of this notice is to announce a stakeholder meeting on the E-Verify Program. This meeting will help USCIS identify strengths and weaknesses of the E-Verify Program's implementation under Arizona law from multiple perspectives and will help assist the evaluation staff in prioritizing future research topics. DATE AND TIME: The meeting will be held on Monday, March 9, 2009, from 9 a.m. to 5 p.m.

**ADDRESSES:** The meeting will be held at the Pointe Hilton Squaw Peak, 7677 North 16th Street, Phoenix, Arizona 85020.

FOR FURTHER INFORMATION CONTACT: To RSVP for the meeting: Dr. Denise Glover, Westat, 1650 Research Boulevard, Rockville, MD 20850. Telephone: (301) 251–2269; Fax: (301) 294–3992. E-mail: *deniseglover@westat.com*. USCIS contact: Sara Speckhard, Research and Evaluation Division, Office of Policy and Strategy, U.S. Citizenship and Immigration Services, 20 Massachusetts Avenue, NW., Washington, DC 20529– 2140 Telephone: (202) 272–1470. Email: *sara.speckhard@dhs.gov*.

## SUPPLEMENTARY INFORMATION:

## Background

Section 403—Illegal Immigration Reform and Immigrant Responsibility Act of 1996 (IIRIRA)

On September 15, 1997, the Immigration and Naturalization Service